Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies

被引：0
|
作者：
Takuma Imakita
Kohei Fujita
Takanori Ito
Zentaro Saito
Issei Oi
Osamu Kanai
Hiromasa Tachibana
Satoru Sawai
Tadashi Mio
机构：
[1] National Hospital Organization Kyoto Medical Center,Division of Respiratory Medicine, Center for Respiratory Diseases
[2] National Hospital Organization,Division of Thoracic Surgery, Center for Respiratory Diseases
[3] Kyoto Medical Center,undefined
来源：
Discover Oncology | / 14卷
关键词：
Cytotoxic T-lymphocyte-associated protein-4; Tumor proportion score; Immune checkpoint inhibitor; Immune-related adverse event; Objective response rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
    B Homet Moreno
    A Ribas
    [J]. British Journal of Cancer, 2015, 112 : 1421 - 1427
  • [42] Sick sinus syndrome associated with anti-programmed cell death-1
    Hsu, Chien-Yi
    Su, Yu-Wen
    Chen, San-Chi
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [43] Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
    Moreno, B. Homet
    Ribas, A.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1421 - 1427
  • [44] Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer: Three case reports
    Zheng, Yun
    Zhu, Chen-Yu
    Lin, Jing
    Chen, Wang-Shan
    Wang, Yu-Jie
    Fu, Hong-Ye
    Zhao, Qiong
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (30) : 11049 - 11058
  • [45] Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer:Three case reports
    Yun Zheng
    Chen-Yu Zhu
    Jing Lin
    Wang-Shan Chen
    Yu-Jie Wang
    Hong-Ye Fu
    Qiong Zhao
    [J]. World Journal of Clinical Cases, 2022, 10 (30) : 11049 - 11058
  • [46] Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Piejko, Karolina
    Galus, Lukasz
    Ziolkowska, Barbara
    Kieszko, Stanislaw
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Zemelka, Tomasz
    Kubiatowski, Tomasz
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    [J]. MELANOMA RESEARCH, 2021, 31 (01) : 49 - 57
  • [47] Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy
    Shah, Kaustav P.
    Song, Haocan
    Ye, Fei
    Moslehi, Javid J.
    Balko, Justin M.
    Salem, Joe-Elie
    Johnson, Douglas B.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2020, 8 (07) : 851 - 855
  • [48] A subcutaneous abscess following anti-programmed cell death 1/programmed death-ligand 1 antibody treatment for lung cancer
    Sugino, Hitomi
    Sawada, Yu
    Nakamura, Motonobu
    [J]. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2022, 5 (03) : 104 - 105
  • [49] The path forward for anti-programmed cell death-1 therapy in gliomas
    Majd, Nazanin
    Kamiya-Matsuoka, Carlos
    de Groot, John
    [J]. CURRENT OPINION IN NEUROLOGY, 2019, 32 (06) : 864 - 871
  • [50] Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis
    Yamada, Takahiro
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Miyamoto, Shintaro
    Nakashima, Taku
    Iwamoto, Hiroshi
    Hirata, Shintaro
    Fujitaka, Kazunori
    Hamada, Hironobu
    Sugiyama, Eiji
    Hattori, Noboru
    [J]. INTERNAL MEDICINE, 2019, 58 (21) : 3129 - 3132
12345